The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first‐line therapy for patients with metastatic castration‐resistant prostate cancer

BACKGROUND: To explore whether metastatic castration‐resistant prostate cancer (mCRPC) patients with distinct intraductal carcinoma of the prostate (IDC‐P) subtypes respond differently to abiraterone and docetaxel treatment. METHODS: We retrospectively analyzed data of 170 mCRPC patients receiving a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhipeng, Zhu, Sha, Zhao, Jinge, Nie, Ling, Chen, Xueqin, Zhang, Mengni, Chen, Ni, Sun, Guangxi, Chen, Junru, Ni, Yuchao, Dai, Jindong, Liu, Zhenhua, Tao, Ronggui, Zhang, Xingming, Zhu, Xudong, Zhang, Haoran, Liang, Jiayu, Wang, Zilin, He, Ben, Shen, Pengfei, Zeng, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290811/
https://www.ncbi.nlm.nih.gov/pubmed/34435696
http://dx.doi.org/10.1002/pros.24215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290811/
https://www.ncbi.nlm.nih.gov/pubmed/34435696
http://dx.doi.org/10.1002/pros.24215

Ejemplares similares